Oral CGRP therapies top migraine market, as all boats rose in 2Q23

After a first-quarter slump in sales for most CGRP inhibitors, the companies behind all seven marketed agents reported revenue increases in 2Q23, with Pfizer’s Nurtec reaching new heights at $247 million in 2Q sales.

In addition to being an oral therapy, Nurtec ODT rimegepant is indicated for both prevention and treatment of migraine. Pfizer Inc. (NYSE:PFE) obtained the CGPR antagonist in its $11.6 billion acquisition of Biohaven Pharmaceutical Holding Co. Ltd., which closed in 4Q22. Then in March of this year, FDA approved Zavzpret zavegepant as the first CGRP nasal spray for migraine, giving the pharma its second approved therapy from the acquisition. Pfizer has yet to report sales for Zavzpret...